Dear [Redacted]

We are pleased to present the attached summary of our discussions with your team multiple times in the past month and have had the chance to present the needs of the company.

We have structured the document in 4 sections:

1. 
2. 
3. 
4. 

Our Vaccine is based on mRNA technology: we encode the structure for the full length spike Coronavirus protein on mRNA and bring this genetic information to human cells. Upon intramuscular injection, the cells uptake the information and intracellular machinery expresses the spike protein. At no time do we handle active virus, nor use adenoviruses and thus can produce multiple products in the same manufacturing plant.

With our proprietary optimization process, CureVac's vaccine technology secures both high levels of protein produced in the cells and appropriate activation of innate immunity. This helps to activate immune system in an efficient and natural way.

Our SARS-CoV-2 preclinical data demonstrates (Figure below) a...
CureVac will manufacture up to company needs. The objective is to have as much vaccine at hand when it is potentially approved.

We expect to spend up to this latter figure will depend on the dose that is established in the clinic and consequent needed dilution.

Assuming the optimum dose determined in the clinical trial is the batches produced, this certainly depends on the concrete dose per vaccination finally determined on the basis of the clinical data.
In the short run, CureVac will present the vaccine in a

Should the vaccine be successful, the Company will

As previously discussed, discussions with

This pre-investment would then to be

2.

The company expects to shortly start

Regular exchanges with the

CureVac has reached out to

To be sufficiently powered, it is expected that such

The company expects this international trial to

CureVac has started the preparation

3.

CureVac needs support now on:

•

•

•

4.

CureVac would recognise the

•

•

•
We understand that the EC has an

We look forward to exchanging at your earliest convenience,

Yours Sincerely,